Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005627 · ClinicalTrials.gov registry record · Phase 1
Estramustine, Docetaxel, and Carboplatin in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00005627: Completed Phase 1 study, sponsored by Dana-Farber Cancer Institute.
NCT00005627 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005627, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of estramustine, docetaxel, and carboplatin in treating patients who have prostate cancer that has not responded to hormonal therapy.
Interventions
- DRUG carboplatin
- DRUG docetaxel
- DRUG estramustine phosphate sodium
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-03 |
| Est. Completion | 2003-04 |
| Phase | Phase 1 |
What the finished NCT00005627 record still lists
NCT00005627 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which carboplatin is the first listed.
NCT00005627 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00005627 about?
NCT00005627 is a clinical study titled "Estramustine, Docetaxel, and Carboplatin in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of estramustine, docetaxel, and carboplatin in treating patients who have...
What is the current status of trial NCT00005627?
This trial is currently completed. It is a Phase 1 study. The study started on 1999-03. Estimated completion is 2003-04.
What interventions are being tested in trial NCT00005627?
The interventions under investigation include: carboplatin (DRUG), docetaxel (DRUG), estramustine phosphate sodium (DRUG).
Who is sponsoring clinical trial NCT00005627?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia